H. Lundbeck, European authorities approve marketing of Serdolect®

The CHMP (Committee for Medicinal Products for Human Use, an EMEA committee) has recommended that the marketing restrictions for Serdolect® can be lifted and that Serdolect® can be marketed according to the SPC (Summary of Product Characteristics). Serdolect® is a drug for the treatment of schizophrenia, and the drug is expected to become available for normal prescription in Europe and is expected to be launched in the first countries in the 2nd half of 2005.